Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Hochhaus, Andreas; A. Larson, Richard; Guilhot, François; P. Radich, Jerald; Branford, Susan; P. Hughes, Timothy; Baccarani, Michele; W. Deininger, Michael; Cervantes, Francisco; Fujihara, Satoko; Ortmann, Christine-Elke; D. Menssen, Hans; Kantarjian, Hagop; G. O’Brien, Stephen; Druker, Brian

doi:10.1056/nejmoa1609324

Public

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Published in New England Journal of Medicine • Mar 8, 2017

Authors:

Andreas Hochhaus

Richard A. Larson

François Guilhot

Abstract

BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. METH...

Subject

Medicine

Imatinib

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!